Cute fluffy welsh pembroke corgi dog enjoying cuddle of vet doctor sitting on squats in front of pet owner and consulting her in clinics
Merck Animal Health has received approval from the Food and Drug Administration (FDA) for a groundbreaking long-acting flea and tick treatment for dogs. The new injectable product, named Bravecto Quantum, is set to protect dogs aged six months and older from fleas and ticks for durations ranging from eight to twelve months. This approval, announced on February 5, 2024, marks a significant advancement in veterinary medicine.
Bravecto Quantum is notable for being the first FDA-approved treatment that offers such extended protection against common canine parasites. According to the FDA, it effectively prevents infestations from black-legged ticks, American dog ticks, and brown dog ticks for up to one year, while also addressing lone star tick infestations for a period of eight months.
Details on Administration and Safety
The treatment will require a prescription from a licensed veterinarian, who will ensure proper administration and monitor any potential adverse reactions. Veterinarians will also provide guidance for dog owners regarding the treatment intervals, which may vary based on the specific species of ticks prevalent in the area.
The active ingredient in Bravecto Quantum, fluralaner, belongs to the isoxazoline class of drugs. While these products are widely used for flea and tick control, the FDA has noted that they can be associated with neurological reactions in some pets, including muscle tremors and seizures. Merck Animal Health advises caution when using this product in dogs with prior seizures or neurological disorders.
Veterinary clinics across the United States are expected to begin offering Bravecto Quantum in March 2024. The company has positioned the product as the leading systemic option for longer-lasting flea and tick prevention, significantly enhancing the available choices for pet owners.
Merck’s Business Expansion and Future Plans
In addition to the FDA approval news, Merck is making a substantial investment in its manufacturing capabilities with plans to construct a new $1 billion biologics manufacturing facility in Wilmington, Delaware. This facility aims to bolster the supply chain for animal health products and bring more manufacturing jobs back to the United States. Merck CEO Robert Davis discussed the initiative during a recent appearance on “Mornings with Maria,” emphasizing the company’s commitment to the U.S. market.
Merck Animal Health is a key segment of the broader Merck pharmaceutical company, which reported $15.53 billion in sales during the first quarter of 2024. Approximately $1.6 billion of that revenue was generated from the animal health division. As the company prepares to release its second-quarter financial results later this month, the approval of Bravecto Quantum and the new facility in Delaware highlight Merck’s strategic focus on expanding its footprint in the animal health market.
The introduction of Bravecto Quantum not only enhances the options available for dog owners but also signifies Merck’s continued innovation and leadership in the animal health sector. As the company moves forward, the combination of new product offerings and investment in manufacturing capabilities positions it well for future growth.
